Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic ...
Lutathera plus Sandostatin improved progression-free survival in patients with advanced gastric neuroendocrine tumors, research showed. Patients with advanced gastric neuroendocrine tumors (NETs) who ...
The FDA approved lutetium Lu 177 dotatate for the treatment of pediatric patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including ...
Lutathera was approved for patients 12 or older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, the FDA announced. The Food and Drug Administration (FDA) approved Lutathera (lutetium ...
Credit: Getty Images. The NETTER-2 trial included patients with newly diagnosed SSTR-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors. First-line treatment with lutetium ...
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to ...
The diagnosis of NETs is often delayed and approximately 10% to 20% of pediatric patients are diagnosed with metastatic disease. The approval was based on the NETTER-P trial, which evaluated Lutathera ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results